CALZF (Polynovo) Debt-to-Asset : 0.14 (As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Polynovo Debt-to-Asset?

Polynovo's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.68 Mil. Polynovo's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $8.53 Mil. Polynovo's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $72.19 Mil. Polynovo's debt to asset for the quarter that ended in Jun. 2024 was 0.14.

Polynovo Debt-to-Asset Historical Data

The historical data trend for Polynovo's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo Debt-to-Asset Chart

Polynovo Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.27

0.26

0.31

0.17

0.14

Polynovo Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.31	0.20	0.17	0.16	0.14

Competitive Comparison of Polynovo's Debt-to-Asset

For the Medical Devices subindustry, Polynovo's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Polynovo's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Polynovo's Debt-to-Asset falls into.

Polynovo Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Polynovo's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.683	+	8.529)	/	72.191
	=	0.14

Polynovo's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.683	+	8.529)	/	72.191
	=	0.14

Polynovo (OTCPK:CALZF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Polynovo Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Polynovo's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Polynovo Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (OTCPK:CALZF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

MFJ:Germany PNV:Australia

Address

320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207

Website

https://www.polynovo.com

Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.